Company profile: DBV Technologies
1.1 - Company Overview
Company description
- Provider of investigational epicutaneous immunotherapy products for food allergies and other immunological disorders via the Viaskin technology platform, including Viaskin Peanut, a patch delivering small amounts of peanut protein to the skin. Also developing Viaskin-based approaches for other food allergies, an investigational diagnostic for non-IgE-mediated milk allergy, and non-invasive vaccine delivery.
Products and services
- Viaskin Technology Platform: Architects an epicutaneous (EPIT) platform delivering biologically active compounds through the skin to the immune system, targeting treatment of food allergies and other immunological disorders
- Viaskin Peanut: Engineers an investigational patch-based immunotherapy that treats peanut allergies by delivering small amounts of peanut protein to the skin
- Viaskin for Other Food Allergies: Develops an EPIT-based extension of the Viaskin platform to treat various food allergies beyond peanuts
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to DBV Technologies
Ampio Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies targeting inflammatory conditions, including OA-201, a small molecule formulation explored as a potential treatment for osteoarthritis of the knee and other joints.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ampio Pharmaceuticals company profile →
Rigel Pharmaceuticals
HQ: United States
Website
- Description: Provider of small-molecule drugs for autoimmune, cancer and metabolic diseases, offering REZLIDHIA (olutasidenib) for relapsed/refractory AML with IDH1 mutation and TAVALISSE (fostamatinib) for adult chronic ITP; pipeline includes R289 for LR-MDS, milademetan (MDM2) for liposarcoma with Daiichi Sankyo, bemcentinib (AXL) for NSCLC with BerGenBio, and R552 (RIPK1) for rheumatoid arthritis with Eli Lilly.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rigel Pharmaceuticals company profile →
Resolvyx
HQ: United States
Website
- Description: Provider of therapeutics based on small molecule lipid mediators for the treatment of inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Resolvyx company profile →
OMass Therapeutics
HQ: United Kingdom
Website
- Description: Provider of drug discovery leveraging novel mass spectrometry, offering the OdyssION platform that uses native mass spectrometry and custom chemistry to study target interactions in native ecosystems, and a small molecule pipeline targeting solute carriers, inflammasome complexes, and GPCRs for orphan and immunological diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OMass Therapeutics company profile →
Therakos
HQ: United States
Website
- Description: Provider of extracorporeal photopheresis immune modulation therapy to enhance immunologic response. Offers the THERAKOS CELLEX Photopheresis System used with UVADEX (methoxsalen) Sterile Solution to treat skin manifestations of CTCL, plus single-use procedural kits. Provides training via THERAKOS INSTITUTE, MyTHERAKOS portal documentation, and 24/7 customer, clinical, technical and product support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Therakos company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for DBV Technologies
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to DBV Technologies
2.2 - Growth funds investing in similar companies to DBV Technologies
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for DBV Technologies
4.2 - Public trading comparable groups for DBV Technologies
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →